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Abstract
Background: Health care expenditures (HCE) are known to steepen with increasing age, but the contributions of
biological age, morbidity, or proximity to death as cost drivers are debated. Age-associated HCE growth can be
studied across two dimensions: within fixed groups of persons with the same birth year followed over time (birth
cohort), or the same age classes (e.g. 66 to 70 year olds) at different time points (age-class analysis). Using health
insurance claims data including morbidity and mortality information, HCE growth was analyzed in Swiss mandatory
health insurance for the years 1996 to 2011 and compared across the two age dimensions.
Results: Deflated HCE were analyzed for 104,000 persons from three birth cohorts (1921-25, 1926-30, 1931-35).
Two-part regression models were adjusted for proximity-to-death (death within same or next calendar year) and
morbidity indicators (hospitalization, high drug expenditures, and pharmaceutical cost groups from 2006 onwards).
When analyzing HCE growth within birth cohorts, controlling for survival and morbidity status decreased age-associated
HCE estimates by 31% to 51% compared to crude age averages. The total HCE volume share of decedents rose from
19% to 31% in the 1931-35 birth cohort and from 28% to 51% for the 1921-25 birth cohort.
The analysis of same age classes (e.g. 71-75 year olds) over different years revealed no HCE growth (steepening) in
excess of deflation for groups aged 75 years or less, and only moderate HCE growth for those ≥76 years. For the 76+
age classes, the population fraction of decedents decreased by -3% (age 76-80) and -15% (age 81-85) over time, whilst
the total HCE volume share of decedent-associated HCE increased by +16% and +9%, with an HCE growth of +3.2%
and +2.5% per year.
Conclusions: HCE growth was dominated by end-of-life HCE, but residual age-associated HCE growth remained
pertinent, the extent of which however depended on morbidity indicator definitions. A better understanding of shifts
in chronic disease prevalence with rising age, as well as associated HCE and survival impacts of treatment will be key for
further refining future HCE projections.
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Introduction
The question whether age is a true driver of health care ex-
penditure (HCE) growth has substantial societal relevance
because it is feared that demographic aging, defined as an
increasing share of elderly persons and a rising average
age, may bring many social health insurance systems to
their limits. Yet, the relationship between aging and HCE
growth is not entirely understood. For example, the “red
herring theory” postulates that the association between
rising age and HCE growth is actually driven by
proximity-to-death. [1] If true, this would imply that
additional life years gained would be spent in relatively
good health and therefore not automatically trigger an ac-
celerated overall HCE growth. [2] By contrast, if medical
treatments among elderly were to prolong lifespan but also
lead to a lifelong dependency on follow-up care, then
population aging may indeed contribute to substantial fur-
ther HCE growth. Given this range of possible scenarios, a
better understanding of the relationship between aging and
HCE growth is key in order to tackle future challenges of
demographic aging in health care systems.
Using longitudinal, individual-level Swiss health insur-
ance claims data from more than 104,000 elderly (>60
years), the present study aimed to dissect the impact of
proximity-to-death on general HCE growth over a time
period of 15 years The availability of this complete panel
data set (including morality data) allowed analyses of the
data in two age/time dimensions. First, analyses within
birth cohorts allowed deeper insights into drivers for
age-associated HCE growth, whereas HCE comparisons
across specific age classes in different calendar years
(e.g. HCE of 61-65 year olds in 1997 and 2001) helped
to acquire a better understanding of broader patterns
of health status and care utilization over time. Thereby,
the findings are contributing to ongoing scientific de-
bates regarding identification of HCE drivers in aging
societies (analysis 1), whilst the second analysis ad-
dressed the as-of-yet unsolved question whether HCE
growth is truly more pronounced in older age classes as
postulated by some studies. [3, 4]
This manuscript is structured as follows: The next sec-
tion discusses the database and the analytic strategy. The
results section starts with a description of the study sample
(with emphasis on HCE and mortality rates) and proceeds
with a presentation of regression analyses results and an
analysis of HCE growth rates for different sub-populations
defined by morbidity status and proximity-to-death. The
paper closes with a discussion section and remarks on
study strengths and caveats for interpretation.
Methods
Literature Search
Overall, the notion of rising HCE with increasing age is
uncontested [5, 6]. Nevertheless, opinions diverge on the
main causes of age-associated HCE growth. Possible
drivers reported in the literature are, for example, shifts
in morbidity-related factors, technological innovations,
and proximity-to-death. This latter aspect has gained
prominence as the “red herring hypothesis”, put forth by
Zweifel and colleagues. [1, 7] Based on their empirical
analysis of HCE data from survivors and decedents, the
authors observed that the relevance of age parameters
diminished once variables for time-to-death were in-
cluded in the models. This finding led to their claim that
aging is in fact a distraction from the true causes of
age-related HCE increases, with the real reason being
the increasing proximity-to-death. Their work has
sparked an ongoing debate on, and long line of studies
investigating, drivers of age-related HCE growth.
The existing literature can broadly be grouped into
micro-econometric analyses of HCE data (e.g. from
health insurers), which were testing the statistical signifi-
cance of time-to-death and aging parameters in regres-
sion models (mostly two-part regressions) for various
HCE components (e.g. long-term care or prescription
drug use) and by employing differing morbidity adjust-
ments. [7–10] A second strand of research approached
the question from a macro perspective via a combination
of micro-data analyses and population-level simulations
of HCE growth [11–16]. The majority of both study types
seem to acknowledge a major role of proximity-to-death as
HCE driver, but some diverge in their assessment of whether
there is room for aging as an additional, relevant factor. [14]
More recently, the scientific debate has shifted towards clari-
fying the role of morbidity viz. proximity-to-death. Indeed,
some authors maintain that proximity-to-death is in fact a
proxy for morbidity status. [10, 17]
The topics of demographic aging and rising HCE are
also pertinent for Switzerland. Currently, elderly persons
aged 65 and older account for 43% of all HCE accrued
in mandatory health insurance, and projections foresee a
rise in the percentage of elderly from 18% in 2015 to
26% by the year 2045 [18], with significant implications
for HCE growth [15]. Several Swiss studies have already
looked into the relationship between HCE increases and
rising age. For example, by analyzing insurance claims
data, Felder and colleagues have repeatedly found that
proximity-to-death is a much stronger determinant for
cost increases in health care than age [1, 7, 8]. Along the
same lines, Steinmann and colleagues confirmed a dom-
inant role of proximity-to-death but further also empha-
sized the need for distinction between mortality- and
morbidity-related costs in the context of HCE growth
predictions [19]. This view is challenged by Colombier
[14] who performed cost projections informed by
long-term macro-data analysis. These analyses main-
tained strong age-dependencies and hence predicted
substantial cost growth in the health care sector as a
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result of population aging in Switzerland [14]. Along the
same lines, as a result of demographic aging and higher
HCE expenditure growth in older age groups, von Wyl
and Beck predicted a substantial intergenerational shift
in the burden of HCE from older to younger age groups,
which is mediated through the redistributive effects of
risk adjustment in mandatory health insurance [20].
The present analysis extends these findings by further
investigating the role of morbidity and proximity-
to-death as drivers for the previously observed higher
HCE growth in older age groups over a 15 year period.
Moreover, an additional novelty of this manuscript is the
two-dimensional growth analysis within birth cohorts
and across age classes at different time points, which al-
lows a dissection of cohort- and calendar-year specific
contributions to cost growth.
Study objective
The main objective of this study was to assess the im-
pact of proximity-to-death and morbidity (as defined by
the three proxy measures introduced below) on HCE
over time. The analysis comprised of three steps. The
birth cohort analysis aimed at revealing age-associated
HCE growth patterns over a duration of 15 years (Fig. 1,
blue boxes). By contrast, the age class analysis focused
on the evolution of HCE within specific age classes over
time (e.g. the groups of 71-75 year olds insured in the
years 1996 to 2006; Fig. 1, green boxes). Results from
this analysis were indicative of more general patterns of
health care consumption, and possibly also of
age-specific health status changes over time. Finally, the
decomposition step employed results from the “birth co-
hort” and the “age class” analyses in order to assess the
importance of different drivers of HCE growth, that is,
of proximity-to-death, morbidity indicators, as well as
unspecified, residual age-associated factors at the popu-
lation level.
Data Sources
This study used individual-level HCE data from the Swiss
social health insurance, which is mandatory for all persons
living in Switzerland and offers comprehensive coverage
of all essential medical in- and outpatient treatments.
Anonymized data was provided by CSS Insurance, the
largest, nationwide operating Swiss health insurer, which
has a market share of approximately 16%. The data were
reimbursement claims covering a 15-year period (from
1996 to 2011). Because costs for inpatient hospital stays
are shared evenly between cantons and insurers, they were
doubled for the purpose of this analysis. The database
contained annualized HCE per insured, as well as the
coverage duration for a given year (ranging from 1 to 12
months). To account for partial coverage years (e.g. due to
death), yearly HCE were rescaled to monthly HCE by
dividing total annual HCE by coverage months.
Fig. 1 Schematic depiction of study design
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All HCE were deflated on the basis of overall cost
growth in Swiss mandatory health insurance. The defla-
tion factors were derived from data on Swiss risk adjust-
ment and included annual HCE growth rates for all
adult insured between 18 to 60 years of age (on average
3.3% per annum).
The population included in this study consisted of
persons who were born between 1921 and 1935. For
the results presentation, these individuals were
grouped into three birth cohorts of persons born be-
tween 1921-1925, 1926-1930, and 1931-1935 (i.e. per-
sons aged 71 to 75, 66 to 70, and 61 to 65 at
baseline in 1996, respectively), whose survival status
and HCE were studied over the 15-year observation
period. The study population was restricted to per-
sons with at least 12 months of total follow-up and
insurance coverage until death or the full observation
period.
Variables
Swiss insurers collect demographic information (age,
gender), as well as the year of death (although not the
cause). Mortality information was available up until the
year 2013. Proximity-to-death was defined as years until
the event, with 0 indicating death in the same calendar
year, 1 in the following calendar year, etc. For the ana-
lysis, proximity-to-death greater than 2 years were cen-
sored (i.e. set to 2 years) because HCE dropped
markedly beyond 2 years prior to death and remained at
approximately similar levels (Fig. 2). Larger censoring
cut-offs (3 years and more) were explored in sensitivity
analyses but did not materially alter results (not shown).
In Switzerland, outpatient diagnostic information
are not routinely available to health insurers (and in-
patient diagnoses only since 2012). However, the data
contained information on hospitalizations, as well as
nursing home stays and amounts of outpatient drug
expenditures, which allowed emulation of some of the
morbidity indicators used by Swiss risk adjustment
over the full observation period (see below, [21, 22]).
In particular, these morbidity indicators record
whether a person had nursing home stays or inpatient
hospitalization in the prior calendar years, as well as
high medication costs above a pre-defined threshold
in the previous calendar years. These indicators were
developed, validated, and are implemented in the
Swiss risk adjustment scheme and strike a comprom-
ise between ease of estimation and predictive power.
For the purpose of this study, high medication costs
were defined as outpatient prescription drug costs
above CHF 2750 at baseline. For subsequent analysis
years, this threshold was adjusted by yearly HCE cost
growth (amounting to approx. CHF 5000 in 2015,
which corresponds to the threshold used in Swiss risk
adjustment). The only diagnostic information were
pharmaceutical costs groups (PCG), which were avail-
able in this dataset from 2006 onwards. These PCG
are derived routinely from outpatient drug
Fig. 2 Crude monthly HCE, by survivor status. The x-axis represents years to death, whereby 0 stands for death in same calendar year, 1 equals
death in following year, etc
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prescriptions for 21 chronic illnesses that require
continuous treatment with disease-specific medica-
tions (such as those for HIV, Diabetes, or depres-
sion). [21, 23]
Analysis Strategy
Multivariable regression analyses of increasing complex-
ity were employed to factor out the effects of imminent
death (i.e. within the same or next calendar year) and
morbidity (as indicated by hospitalizations, nursing
home stays, or high outpatient drug expenditures in the
prior calendar year).
For the regression analyses, average monthly health
care expenditures in Swiss Francs (1 CHF equaled 0.86
Euro or 1 US$ in July 2018) were extracted for the years
1997 through 2011 and analyzed by means of two-part
models (using robust standard errors). The two-part
models consisted of a logit-model part for the probabil-
ity of having >CHF 0 health care expenditures in a given
period. The second part consisted of a generalized linear
model (glm) for the health care expenditure amount of
persons with positive HCE. Based upon exploratory ana-
lyses and comparisons of goodness-of-fit criteria
(Aikaike’s Information Criterion, AIC), the generalized
gamma method was chosen for all two-part regression
implementations in this study (not shown).
The two-part regression framework used in this study
can be described by the following two equations for the
basic model
Pr HCE > 0ð Þ ¼ sexþ baseline ageþ baseline age2
þcalendar year dummies
þ baseline age  calendar year dummiesð Þ
þ baseline age  sexð Þ
(which is the logit part) and
Pr HCEð jHCE > 0Þ ¼ sexþ baseline ageþ baseline age2
þcalendar year dummies
þ baseline age  calendar year dummiesð Þ
þ baseline age  sexð Þ;
representing a generalized linear model (glm) with log
link and gamma distribution.
The following variables and attributes were ana-
lyzed: sex (male/female), age at baseline as a continu-
ous variable, and calendar years as dummy variables.
The interaction terms were chosen a priori based on
existing literature (e.g. [10, 17, 24]).
Model specifications of the logit and glm parts for
the mortality- (i.e. proximity-to-death) and morbidity-
adjusted model were as follows:
Pr HCE > 0ð Þ HCEð jHCE > 0Þ ¼ sexþ baseline age
þbaseline age2
þcalendar year dummies
þhospitalization
þnursing home stay
þhigh drug expenditures
þtime to death
as well as two-way interactions terms baseline age * sex,
baseline age * calendar years, baseline age * hospitalization
in prior year, time to death * hospitalization in prior year,
baseline age * time to death, and calendar years * time to
death. Again, interaction terms were chosen a priori based
on existing literature and subject knowledge about cost
trajectory shapes of end-of-life HCE in Switzerland. [6]
A third regression model considered only mortality
adjustments but no morbidity-related variables and
interaction terms. Moreover, in a sensitivity analysis the
full mortality- and morbidity-adjusted model was
complemented with PCGs, which were available from
2006 onwards.
The two-part estimation was performed on logarithms
of HCE, and regression model estimates were then
back-transformed into Swiss Francs according to the fol-
lowing equation (for individual i):
HCEið j xiÞ ¼ Pr HCEi > 0ð j xiÞ  HCEið jHCEi > 0; xiÞ
Confidence Intervals for predictions on the original
HCE scale were estimated via bootstrapping with 500
replications. For presentation, the model results were ag-
gregated over three birth cohorts [1921-1925,
1926-1930, and 1931-1935] to allow for the longitudinal
and cross-sectional comparisons outlined in Fig. 1.
Along the same lines, calendar time was available in full
for regression models but is – for ease of interpretation
- illustrated only for four calendar years that are ap-
proximately 5 years apart (1997, 2001, 2006, 2011), in
order to ensure a full shift of all age classes into the next
higher category. The year 1997 was chosen as the base-
line year instead of 1996 because some analyses use
morbidity indicators that are based on 1-year lagged in-
formation, which were not available in this dataset
before 1996.
In a final step, it was explored as to what extent
imminent death may act as a driver of HCE growth
across different age groups. The general approach was to
group all insured into three hierarchical groups in a given
reference year: those who died within two years (s ≤ 1),
those with morbidity indications but survival beyond two
years (s > 1, m = 1), and those without morbidity indicators
and survival beyond two years (s > 1, m = 0). Next, each
group’s share of the overall cost volume in a reference year
was calculated according to the following equation, with n
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denoting number of individuals and HCE representing
regression coefficients.
The total HCE volume V in a given year y for a given
birth cohort b is defined as follows.
Vb;y ¼ nb;y; s≤1;m∈f0;1g  HCEb;y;s≤1;m∈f0;1g
þ nb;y;s>1;m¼1  HCEb;y;s>1;m¼1 þ nb;y;s>1;m¼0
 HCEb;y;s>1;m¼0
The contributions F of each group to cost volume
increase is further calculated by
(for decedents)
Fb;y;s≤1;m∈ 0;1f g ¼ nb;y;s≤1;m∈ 0;1f g  HCEb;y;s≤1;m∈ 0;1f g
 
=Vb;y
(for persons with morbidity indicators)
Fb;y;s>1;m¼1 ¼ nb;y;s>1;m¼1  HCEb;y;s>1;m¼1
 
=Vb;y
and (for persons without morbidity indicators)
Fb;y;s>1;m¼0 ¼ nb;y;s>1;m¼0  HCEb;y;s>1;m¼0
 
=Vb;y
All models and calculations were implemented using
Stata 13 and the stpm package. [25]
Results
Descriptive analyses of the study sample and HCE
The full database contained information from approxi-
mately 125,000 individuals. However, the selection
criterion led to the exclusion of 17% of individuals who
either switched insurance carriers or did not have 12
months of follow-up time. Excluded persons were more
likely males but did not differ significantly from included
persons with respect to HCE distribution (median CHF
125 [interquartile range 32; 331] per month for excluded
vs. CHF 123 [41; 295] for included persons, rank-sum
p-value 0.195).
The final sample contained information of 104,215
Swiss insured who were at least 61 years old at baseline.
As expected, women were in the majority (59%). Fur-
thermore, the birth cohort distribution looked as follows.
In 1997, 38% were between 61 to 65 years old
(1931-1935 birth cohort), 33% were aged between 66
and 70 (1926-1930 birth cohort), and 30% were between
71 to 75 years old (1921-1925 birth cohort). Of those,
66,175 individuals remained in the analysis until 2011,
and 40% of all individuals died during the observation
period (not shown), with statistically significant differ-
ences across birth cohorts (Additional file 1: Figure S1)
and/or morbidity status (not shown).
Table 1 illustrates averages of deflated monthly HCE,
which increased markedly in the presence of morbidity
indicators and with increasing proximity-to-death, as
well as rising calendar year. The raw data displayed in
Table 1 are complemented by box-and-whisker plots of
monthly HCE by proximity-to-death (Fig. 2), over time
by birth cohort (Figure 3), and by the same age classes
over time (Fig. 4). Figures 2 and 3 confirm the expected
relationships between rising HCE and proximity-
to-death and increasing age, respectively. By contrast,
Fig. 4 shows results for constant age classes over time
and indicates almost no (deflation-indexed) HCE
changes over calendar time. However, HCE increased
Table 1 Descriptive analyses of HCE, stratified by remaining lifetime and analysis year (stratified by survivor status and presence of
morbidity indicators as defined for the mortality and morbidity adjusted model)
Year Subgroup N HCE mean (SD) Females (%) 1931-1935 1926-1930 1921-1925
1997 All 104215 411 (1013) 61794 (59.3%) 38522 (37%) 34758 (33.4%) 30935 (29.7%)
1997 Survivor, no morbidity 82540 246 (571) 49973 (60.5%) 32008 (38.8%) 27617 (33.5%) 22915 (27.8%)
1997 Survivor, with morbidity 17472 747 (1196) 10056 (57.6%) 5583 (32%) 5766 (33%) 6123 (35%)
1997 Deceased 4203 2260 (2944) 1765 (42%) 931 (22.2%) 1375 (32.7%) 1897 (45.1%)
2001 All 95469 455 (962) 58022 (60.8%) 36554 (38.3%) 31914 (33.4%) 27001 (28.3%)
2001 Survivor, no morbidity 71247 265 (500) 44175 (62%) 29082 (40.8%) 23840 (33.5%) 18325 (25.7%)
2001 Survivor, with morbidity 19383 742 (1017) 11647 (60.1%) 6328 (32.6%) 6601 (34.1%) 6454 (33.3%)
2001 Deceased 4839 2104 (2619) 2200 (45.5%) 1144 (23.6%) 1473 (30.4%) 2222 (45.9%)
2006 All 82424 595 (1199) 51821 (62.9%) 33582 (40.7%) 27808 (33.7%) 21034 (25.5%)
2006 Survivor, no morbidity 57562 325 (623) 36794 (63.9%) 25484 (44.3%) 19359 (33.6%) 12719 (22.1%)
2006 Survivor, with morbidity 18839 909 (1186) 11959 (63.5%) 6672 (35.4%) 6527 (34.6%) 5640 (29.9%)
2006 Deceased 6023 2190 (2833) 3068 (50.9%) 1426 (23.7%) 1922 (31.9%) 2675 (44.4%)
2011 All 66175 751 (1453) 43094 (65.1%) 29785 (45%) 22413 (33.9%) 13977 (21.1%)
2011 Survivor, no morbidity 42440 386 (674) 27733 (65.3%) 21391 (50.4%) 14089 (33.2%) 6960 (16.4%)
2011 Survivor, with morbidity 16261 991 (1079) 11051 (68%) 6511 (40%) 5738 (35.3%) 4012 (24.7%)
2011 Deceased 7474 2296 (3210) 4310 (57.7%) 1883 (25.2%) 2586 (34.6%) 3005 (40.2%)
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across age classes as expected, with higher HCE as age
increases.
Results from regression models
Time trends were further explored within birth cohorts
and age classes by use of two-part regression. The full
model output is displayed in Table 2. The model results
meet common, literature based expectations. In particu-
lar, HCE increased with increasing baseline age and
calendar year. Moreover, proximity-to-death was also
associated with higher costs (for models 2 and 3), as
were the morbidity indicators for prior hospitalization,
Fig. 3 Crude monthly HCE plotted per calendar year (inner x-axis labels) and by birth cohort, that is, the same individuals followed over time
(outer x-axis labels)
Fig. 4 Crude monthly HCE per year (inner x-axis label) and by age class, that is, age classes held constant over different time periods (outer x-axis
label). Note that each age class includes individuals from different birth cohorts
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Table 2 Regression results from two-part models
(1) Basic Model
AIC: 18332417
(2) Mortality-adjusted Model
AIC: 18033849
(3) Morbidity- and Mortality-adjusted Model
AIC: 17781023
logit
estimate
t-
value
glm
estimate
t-value logit
estimate
t-
value
glm
estimate
t-value logit
estimate
t-
value
glm
estimate
t-value
Female sex 0.293*** -25.04 -0.202*** -29.08 0.308*** -11 -0.108*** -9.17 0.341*** -12.25 -0.0887*** -10.36
Age at baseline
Age at baseline per
year increase
0.0551*** -14.55 0.0346*** -15.01 0.0550*** -7.42 0.0284*** -9.12 0.0533*** -7.21 0.0293*** -11.61
Age at baseline 2 0.000355 -1.58 -0.0000115 -0.1 0.0000633 -0.12 -0.00022 -1.2 -0.000202 -0.38 -0.000371** -2.75
Int. age at baseline #
female sex
-0.00657*** -3.75 0.00926*** -10.03 -0.00467 -1.15 0.0127*** -8.79 -0.00734 -1.81 0.00825*** -7.75
Calendar year
1997 Ref. Ref. Ref.
1998 0.110*** -4.68 0.0412* -2.29 0.107*** -6.46 0.0300* -2.13 0.104*** -6.02 0.0235 1.47
1999 0.246*** -10.07 0.0694*** -3.84 0.246*** -13.54 0.0638*** -4.21 0.238*** -12.78 0.0479** -3.05
2000 0.410*** -16.12 0.0443* -2.46 0.409*** -20.69 0.0480** -3.14 0.392*** -19.42 0.0225 -1.44
2001 0.417*** -16.23 0.0663*** -3.68 0.414*** -20.39 0.0592*** -3.84 0.386*** -18.6 0.0289 -1.82
2002 0.291*** -11.64 -0.122*** -6.73 0.290*** -14.29 -0.145*** -8.93 0.257*** -12.4 -0.189*** -11.45
2003 0.671*** -24.2 0.151*** -8.34 0.669*** -28.72 0.157*** -9.65 0.677*** -28.66 0.178*** -10.86
2004 0.801*** -27.59 0.208*** -11.43 0.799*** -32.01 0.199*** -12.34 0.751*** -29.58 0.142*** -8.82
2005 0.925*** -30.53 0.233*** -12.79 0.924*** -35.03 0.213*** -12.86 0.871*** -32.61 0.146*** -8.74
2006 1.004*** -31.9 0.298*** -16.21 1.000*** -35.91 0.276*** -16.53 0.952*** -33.72 0.215*** -12.92
2007 1.129*** -34.14 0.366*** -19.87 1.125*** -38.03 0.335*** -20.33 1.081*** -36.07 0.287*** -17.45
2008 1.300*** -36.68 0.387*** -20.91 1.297*** -40.08 0.361*** -21.66 1.241*** -37.88 0.301*** -17.78
2009 1.382*** -37.33 0.455*** -24.32 1.383*** -40.79 0.392*** -23.83 1.325*** -38.57 0.324*** -19.82
2010 1.485*** -37.98 0.452*** -24.02 1.481*** -41.04 0.410*** -24.75 1.420*** -38.9 0.341*** -20.55
2011 1.593*** -38.66 0.525*** -27.69 1.585*** -41.09 0.457*** -27.54 1.527*** -39.07 0.403*** -24.27
Int. age at baseline & calendar year
1998 # Age at baseline 0.000516 -0.16 -0.00227 -1 0.000259 -0.11 -0.00153 -0.91 -0.000105 -0.04 -0.00178 -0.93
1999 # Age at baseline 0.00759* -2.19 -0.000617 -0.27 0.00739** -2.86 -0.000701 -0.39 0.00646* -2.45 -0.00162 -0.84
2000 # Age at baseline 0.00806* -2.22 0.00232 -1.02 0.00721* -2.54 0.00104 -0.56 0.00555 -1.91 -0.000218 -0.11
2001 # Age at baseline 0.0181*** -4.83 -0.000646 -0.28 0.0171*** -5.68 -0.000981 -0.53 0.0148*** -4.83 -0.00354 -1.84
2002 # Age at baseline 0.0135*** -3.72 -0.000105 -0.05 0.0121*** -4.08 -0.00117 -0.6 0.00922** -3.04 -0.00398* -1.97
2003 # Age at baseline 0.0156*** -3.82 -0.000623 -0.27 0.0135*** -3.88 -0.00201 -1.03 0.0121*** -3.43 -0.00363 -1.83
2004 # Age at baseline 0.0178*** -4.11 -0.00119 -0.51 0.0157*** -4.1 -0.00127 -0.65 0.0123** -3.18 -0.00459* -2.29
2005 # Age at baseline 0.0146** -3.22 -0.000473 -0.2 0.0118** -2.9 -0.00159 -0.8 0.00715 -1.74 -0.00606** -2.96
2006 # Age at baseline 0.0193*** -4.01 0.00219 -0.92 0.0157*** -3.6 0.000028 -0.01 0.0107* -2.4 -0.00460* -2.26
2007 # Age at baseline 0.0175*** -3.43 -0.000538 -0.22 0.0138** -2.96 -0.00224 -1.12 0.00842 -1.78 -0.00760*** -3.77
2008 # Age at baseline 0.0157** -2.83 0.00281 -1.16 0.0107* -2.07 -0.000687 -0.34 0.0045 -0.86 -0.00518* -2.49
2009 # Age at baseline 0.0170** -2.89 0.00357 -1.44 0.0128* -2.33 -0.00128 -0.63 0.00498 -0.89 -0.00694*** -3.37
2010 # Age at baseline 0.0198** -3.12 0.00625* -2.48 0.0145* -2.41 -0.00153 -0.75 0.00622 -1.02 -0.00765*** -3.68
2011 # Age at baseline 0.0161* -2.37 0.00374 -1.46 0.00892 -1.35 -0.00219 -1.07 -0.000527 -0.08 -0.00915*** -4.36
Survival status
Death in same
calendar year
1.490*** -10.27 2.562*** -89.94 1.154*** -7.62 2.304*** -71.74
Death in next calendar
year
0.830*** -7.52 1.704*** -55.97 0.477*** -4.26 1.516*** -46.82
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Table 2 Regression results from two-part models (Continued)
(1) Basic Model
AIC: 18332417
(2) Mortality-adjusted Model
AIC: 18033849
(3) Morbidity- and Mortality-adjusted Model
AIC: 17781023
logit
estimate
t-
value
glm
estimate
t-value logit
estimate
t-
value
glm
estimate
t-value logit
estimate
t-
value
glm
estimate
t-value
Survivor Ref. Ref.
Int. survival status # age at baseline
Death in same
calendar year # Age at
baseline
-0.00624 -0.66 -0.0560*** -37.21 -0.00807 -0.84 -0.0452*** -27
Death in next calendar
year # Age at baseline
0.0108 -1.49 -0.0463*** -34.1 0.0101 -1.37 -0.0400*** -25.95
Int. calendar year # survival status
1998 # Death in same
calendar year
0.24 -1.25 -0.0431 -1.21 0.225 -1.16 -0.035 -0.87
1998 # Death in next
calendar year
0.0686 -0.48 -0.0212 -0.51 0.0634 -0.44 -0.0215 -0.5
1999 # Death in same
calendar year
0.0198 -0.1 -0.0682 -1.91 -0.0202 -0.11 -0.0662 -1.74
1999 # Death in next
calendar year
-0.264 -1.93 -0.0658 -1.66 -0.291* -2.09 -0.0393 -0.94
2000 # Death in same
calendar year
0.0206 -0.1 -0.140*** -4.02 -0.0131 -0.07 -0.122** -3.27
2000 # Death in next
calendar year
0.029 -0.19 -0.0541 -1.44 -0.0419 -0.28 -0.106** -2.69
2001 # Death in same
calendar year
-0.0107 -0.05 -0.158*** -4.61 -0.119 -0.6 -0.192*** -5.1
2001 # Death in next
calendar year
0.0993 -0.64 -0.137*** -3.61 0.0289 -0.18 -0.193*** -4.95
2002 # Death in same
calendar year
0.214 -1.07 -0.0730* -2.12 0.0921 -0.46 -0.0944* -2.44
2002 # Death in next
calendar year
-0.19 -1.4 -0.242*** -6.23 -0.242 -1.74 -0.289*** -6.94
2003 # Death in same
calendar year
0.0375 -0.18 -0.332*** -9.23 0.0281 -0.13 -0.296*** -7.81
2003 # Death in next
calendar year
0.0587 -0.37 -0.224*** -6.09 0.0712 -0.44 -0.244*** -6.31
2004 # Death in same
calendar year
0.143 -0.64 -0.341*** -10.55 -0.0105 -0.05 -0.348*** -9.35
2004 # Death in next
calendar year
-0.158 -1.02 -0.270*** -7.62 -0.217 -1.38 -0.312*** -8.22
2005 # Death in same
calendar year
-0.169 -0.82 -0.331*** -9.83 -0.323 -1.56 -0.324*** -8.47
2005 # Death in next
calendar year
-0.00632 -0.04 -0.274*** -7.59 -0.0598 -0.36 -0.307*** -7.87
2006 # Death in same
calendar year
0.18 -0.77 -0.361*** -10.67 0.0315 -0.13 -0.350*** -9.09
2006 # Death in next
calendar year
-0.0632 -0.38 -0.311*** -8.77 -0.157 -0.94 -0.339*** -8.94
2007 # Death in same
calendar year
0.00000638 0 -0.418*** -12.94 -0.151 -0.66 -0.382*** -10.43
2007 # Death in next
calendar year
-0.208 -1.3 -0.321*** -9.24 -0.283 -1.74 -0.347*** -9.22
2008 # Death in same
calendar year
-0.164 -0.74 -0.484*** -14.83 -0.337 -1.51 -0.477*** -12.93
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nursing home stays, or high costs (model 3). Moreover,
the interaction terms improved the AIC model fit (data
not shown). Table 3 offers a different view on the regres-
sion results by showing regression model derived HCE
predictions. The basic model column illustrates predic-
tion averages for the three birth-cohort groups and four
calendar years. Prediction averages increased over calen-
dar years (e.g. from CHF 306 per month in 1997 to CHF
584 in 2011 for the 1931-1935 birth cohort), as well as
across the three birth cohorts (e.g. from CHF 306 in
1997 to CHF 502 for the 1921-1925 birth cohort). The
remaining columns of Table 3 illustrate how age-and cal-
endar year stratified HCE change after controlling for mor-
tality and morbidity status. For example, monthly HCE in
1997 for the 1931-1935 birth cohort decreased from CHF
306 to CHF 213 after morbidity and mortality adjustments.
Of note, these adjustment-driven decreases were even
more pronounced for older birth cohorts (e.g. from CHF
944 to CHF 451 for the 1921-1925 birth cohort in 2011).
Figures 5a (birth cohort) and 6a (age class) plot HCE
estimates over calendar time per birth cohort or age
class. In the birth cohort analysis, there was a widening
gap between basic and survival-adjusted estimates
because basic estimates grew at a higher rate (which im-
plies a rising importance of proximity-to-death on
age-specific HCE averages). Moreover, by applying re-
sults from the morbidity and mortality-adjusted model,
Figure 5b illustrates the share of three groups of insured
(deceased, survivors with morbidity indicators, and sur-
vivors without morbidity indicators) of overall HCE
volume in a given birth cohort and year. The bars show
an increasing importance of decedents for overall HCE
over time, as well as with increasing age. In particular,
the percentage of proximity-to-death related HCE
Table 2 Regression results from two-part models (Continued)
(1) Basic Model
AIC: 18332417
(2) Mortality-adjusted Model
AIC: 18033849
(3) Morbidity- and Mortality-adjusted Model
AIC: 17781023
logit
estimate
t-
value
glm
estimate
t-value logit
estimate
t-
value
glm
estimate
t-value logit
estimate
t-
value
glm
estimate
t-value
2008 # Death in next
calendar year
-0.0271 -0.15 -0.339*** -9.86 -0.133 -0.75 -0.372*** -10.02
2009 # Death in same
calendar year
-0.879*** -4.77 -0.335*** -7.86 -1.061*** -5.68 -0.329*** -6.87
2009 # Death in next
calendar year
-0.0265 -0.15 -0.407*** -12.04 -0.116 -0.64 -0.413*** -11.41
2010 # Death in same
calendar year
-0.745*** -3.83 -0.427*** -12.98 -0.919*** -4.66 -0.386*** -10.32
2010 # Death in next
calendar year
0.0311 -0.17 -0.454*** -13.67 -0.0672 -0.36 -0.466*** -13.14
2011 # Death in same
calendar year
-0.610** -3.01 -0.469*** -13.9 -0.763*** -3.74 -0.422*** -10.82
2011 # Death in next
calendar year
0.167 -0.84 -0.488*** -14.76 0.0776 -0.39 -0.486*** -13.64
Morbidity indicators yes/no
Hospitalization in prior
year
1.491*** -47.65 0.651*** -74.7
Hospitalization in prior
year # Age at Baseline
0.0110* -2.48 -0.00777*** -7.65
High outpatient drug
expenditures in prior
year
4.086*** -33.7 0.893*** -131.66
Nursing home stay in
prior year
3.090*** -26.93 0.841*** -125.92
Int. hospitalization # survival status
Hospitalization in prior
year # Death in same
calendar year
-0.870*** -9.12 -0.250*** -16.96
Hospitalization in prior
year # Death in next
calendar year
0.653*** -4.36 -0.214*** -16.59
Constant 1.460*** -80.67 5.983*** -435.25 1.433*** -57.82 5.772*** -367.05 1.272*** -51.26 5.543*** -383.59
*p < 0.05, **p < 0.01, ***p < 0.001
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increased from 19% to 31% for the 1931-1935 birth co-
hort, from 25% to 39% for the 1926-1930 birth cohort,
and from 28% to 51% for the 1921-1925 birth cohort,
respectively. By contrast, the percentage of HCE stem-
ming from persons with morbidity indicators remained
more constant across birth cohort and time, ranging
from 25% to 33%.
The age class analyses displayed in Figure 6a showed
less HCE variability across calendar time. The younger age
classes exhibited both decreases and increases (e.g. from
CHF 502 per month to CHF 453 for the age class 71-75
between 1997 and 2006 in the basic model), whereas aver-
age HCE in the classes aged 76-80 and above were steadily
increasing over time (e.g. from CHF 553 to CHF 584 for
the age class 76-80 between 2001 and 2011 in the basic
model). Along the same lines, shifts in cost composition
owing to mortality and morbidity were not in one single
direction and relatively small when compared to results
from the birth cohort analyses (Figure 6b). Nevertheless,
the age class analysis also provided some indication that
mortality has declined over time. As illustrated by Table 4,
the population share of deceased persons declined slightly
over calendar time for all age classes (e.g. by -3.3%-points
between 2006 and 2001 for the age class 81-85).
Because the morbidity indicators employed in this ana-
lysis are known to primarily address severe illnesses, the
major findings were subjected to a sensitivity analysis
including pharmaceutical cost groups as additional
morbidity markers (which were only available for the
calendar years between 2006 and 2011, however). The
re-estimated mortality- and morbidity-adjusted model
with additional PCG-adjustments further decreased
HCE estimates for “morbidity-free”, surviving individ-
uals. Relative to the morbidity- and mortality-adjusted
estimates presented in Table 3, the PCG-adjusted model
(last column) led to further decreases, for example from
CHF 288 to CHF 163 (43% reduction, 1931-1935 birth co-
hort in 2006) or from CHF 451 to CHF 286 (37% reduction,
1921-1925 birth cohort in 2011). Moreover, the inclusion of
PCG led to many more persons being classified as having a
chronic illness (74% individuals in 2006 instead of 27% in
the original analysis). This was expected because the mor-
bidity indicators employed in the main analysis were
primarily indicative of severe illnesses requiring inpatient
stays but tended to miss manageable, but prevalent chronic
diseases like diabetes mellitus. This is also illustrated by a
comparison of HCE. In 2006, persons with a PCG-indicated
morbidity had an average HCE accrual of CHF 422 per
month as opposed to CHF 909 in the group with morbidity
indicators as defined for the main analysis.
Health care expenditure growth rates across age classes
A further aim was to compare HCE growth rates over
time across different age classes. Table 4 illustrates total
HCE volume and population size changes for four age
classes between 66 and 85 years of age according to sur-
vival and morbidity status. The main information is
located in the last two columns of Table 4. Crude yearly
HCE change rates were derived from age class specific
HCE volume differences between the two time points but
did not account for changes in population size. Similar to
HCE estimates presented in Figure 6a, overall growth
rates were negative (-1.7%) or slightly positive (0.3%) for
the two younger age classes and exceeding the value of 1%
per year for the two older age classes (1.5% and 1.1%,
respectively). Further noteworthy, in decedents, the
adjustment of growth rates for population size changes
substantially increased growth estimates (e.g. from -0.8%
Table 3 Regression model-derived HCE estimations (based on the regression models shown in Table 2) per birth cohort and year.
Estimates represent HCE per month in Swiss Francs, as well as bootstrapped 95% Confidence Intervals in square brackets
Birth Cohort Year Age classes (1) Basic Model (2) Mortality adjusted (3) Mortality & morbidity-adjusted (4) Mortality & PCG-adjusted
(2006 and later)
1931-1935 1997 61-65 306 [298;314] 270 [264;276] 213 [208;217] -
1931-1935 2001 66-70 343 [335;352] 300 [294;306] 229 [225;233] -
1931-1935 2006 71-75 453 [443;464] 389 [382;397] 288 [283;294] 163
1931-1935 2011 76-80 584 [570;597] 475 [466;484] 354 [348;361] 213
1926-1930 1997 66-70 393 [386;400] 338 [333;344] 260 [256;264] -
1926-1930 2001 71-75 437 [430;445] 373 [367;379] 274 [271;278] -
1926-1930 2006 76-80 579 [569;588] 480 [473;487] 339 [335;344] 197
1926-1930 2011 81-85 744 [732;757] 574 [566;583] 404 [398;410] 245
1921-1925 1997 71-75 502 [489;514] 417 [408;426] 310 [304;317] -
1921-1925 2001 76-80 553 [541;564] 455 [445;464] 320 [314;326] -
1921-1925 2006 81-85 734 [720;749] 582 [570;594] 390 [382;398] 233
1921-1925 2011 86-90 944 [922;966] 684 [670;698] 451 [441;461] 286
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Fig. 5 Panel A: Birth cohort analysis, by baseline age classes and calendar year. HCE are model-based, age-associated predictions from different two-part
models adjusted for age and sex (basic model), survivor status (mortality adjusted), as well as survivor status and morbidity indicators. Panel B: Share of
different groups (by survivor and morbidity status) on overall HCE volume, by birth cohort (outer x-axis) and calendar year (inner x-axis). HCE estimates are
derived from a two-part regression model adjusted for sex, survivor-status, and morbidity status.
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Fig. 6 Panel A: Age class analysis, by calendar year. HCE model-based, age class-associated predictions from different two-part models adjusted
for age and sex (basic model), survivor status (mortality adjusted), as well as survivor status and morbidity indicators. Panel B: Share of different
groups (by survivor and morbidity status) on overall HCE volume by age class (outer x-axis) and calendar year (inner x-axis). HCE estimates are
derived from a two-part regression model adjusted for sex, survivor-status, and morbidity status.
von Wyl Health Economics Review             (2019) 9:9 Page 13 of 16
to 2.3% for decedents from the 71-75 age class). This sug-
gests that, keeping group sizes constant, the HCE volume
for decedents of the same age class rose with increasing
calendar time (with the exception of the 66-70 age class,
where population change adjusted growth was 0%). Of
note, this increase is on top of the general deflation ap-
plied to all HCE. By contrast, overall age class-specific
HCE volume increases were small or even negative when
considering the full sample (i.e. including decedents and
survivors), reinforcing the notion that HCE growth is not
homogenous across all age classes of the elderly.
Discussion
Using a panel dataset of 104,000 Swiss elderly insured,
this study analyzed HCE evolution along two different
age dimensions (birth cohorts and age classes) to
explore the impact of proximity to death on HCE
growth over time. The first analysis dimension focused
on longitudinal cost growth within three birth cohorts,
thereby exploring the effect of “aging” viz. proximity-
to-death and morbidity. As expected HCE increased
non-linearly with rising age, even when adjusting for
imminent death (that is, a remaining lifetime of <2 years
from a given calendar year). Moreover, the HCE volume
share of persons close to death increased markedly as
age and calendar time progressed, ranging from 19% to
51%. This finding implies that proximity-to-death is a
major, but not the only driver of HCE growth with rising
age. Indeed, results from morbidity-adjusted analyses
also pointed to the considerable role of chronic and
hospital-treated illnesses as important factors. An exact
quantification of the impact of morbidities remains diffi-
cult however, as this depends on availability of diagnostic
information and morbidity definitions. For example,
when compared with relatively crude, but time-consist-
ent morbidity indicators based on hospitalizations and
high drug expenditures, a PCG-augmented sensitivity
analysis almost tripled the share of persons with morbid-
ities from one in four to nearly three in four. What is
more, the effect of morbidity was intertwined with prox-
imity to death, which may have led to a general
over-interpretation of the role of mortality on HCE
growth. [17] Indeed, the PCG-based sensitivity analysis
(including persons aged 71 and older in 2006) revealed
Table 4 Regression-derived changes in HCE volume and number of individuals across different age classes over time, stratified by
survivor and morbidity status. All estimates were derived from the mortality- and morbidity-adjusted two-part regression model
Age
Class
Subgroup Comparator groups Population size change HCE volume change (CHF) HCE change rates
(per year)
time
point 1
birth
cohort
time
point 2
birth
cohort
time
point 1
time
point 2
change HCE volume
time point 1
HCE volume
time point 2
change crude population
change corrected
a
66-
70
Overall 1997 1926-
30
2001 1931-
35
34758 36554 105.2% 14437510 13464464 93.3% -1.7% -3.0%
71-
75
Overall 1997 1921-
25
2006 1931-
35
30935 33582 108.6% 16279928 16682277 102.5% 0.3% -0.6%
76-
80
Overall 2001 1921-
25
2011 1931-
35
27001 29785 110.3% 16561328 19265326 116.3% 1.5% 0.5%
81-
85
Overall 2006 1921-
25
2011 1926-
30
21034 22413 106.6% 17906461 18901719 105.6% 1.1% -0.2%
66-
70
Survivors,
morb.
1997 1926-
30
2001 1931-
35
5766 6328 109.7% 3675239 3826840 104.1% 1.0% -1.3%
71-
75
Survivors,
morb.
1997 1921-
25
2006 1931-
35
6123 6672 109.0% 4538328 5038134 111.0% 1.2% 0.2%
76-
80
Survivors,
morb.
2001 1921-
25
2011 1931-
35
6454 6511 100.9% 5330491 5653214 106.5% 0.6% 0.5%
81-
85
Survivors,
morb.
2006 1921-
25
2011 1926-
30
5640 5738 101.7% 5901028 5787366 98.1% -0.4% -0.7%
66-
70
Decedents 1997 1926-
30
2001 1931-
35
1375 1144 83.2% 3580834 2975086 83.1% -4.5% 0.0%
71-
75
Decedents 1997 1921-
25
2006 1931-
35
1897 1426 75.2% 4634687 4293761 92.6% -0.8% 2.3%
76-
80
Decedents 2001 1921-
25
2011 1931-
35
2222 1883 84.7% 5363521 6030700 112.4% 1.2% 2.9%
81-
85
Decedents 2006 1921-
25
2011 1926-
30
2675 2586 96.7% 7045892 7423799 105.4% 1.1% 1.7%
aPopulation change corrected means that HCE volumes for time point 2 were weighted by the population size change occurring between time points 1 and 2 (in
order to emulate equal population sizes).
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that 90% of decedents and 73% of survivors had
PCG-based morbidity indicators (compared with 59%
and 25%, respectively, when applying hospitalization and
drug cost-based indices).
A second analysis looked into the evolution of HCE
for select age classes over time (e.g. all individuals aged
71-75 years in 1997, 2001, and 2006). Interestingly, cost
growth patterns were not unidirectional, and analyses
for younger age classes even suggested decreases over
time. However, as all analyses were performed on deflated
HCE (using nationwide HCE growth among 19-60 year
old persons as a deflator), these results merely suggested
that there was no consistent surplus HCE growth among
elderly within the same age class over time. Analyses by
other groups have found considerable cost profile steepen-
ing by age, that is, higher HCE increases over time for
older age classes. [26] The findings from the age class ana-
lysis supported this notion of steepening for the two oldest
age classes, but not to the extent reported by others. How-
ever, it is possible that actual steepening was underesti-
mated by this study because mandatory health insurance
only accounts for 35% of all HCE in Switzerland. For ex-
ample, the share of nursing home costs covered by social
health insurance is only around 18% and limited to med-
ical care, not including hospitality and other services.
Overall, the findings from this study fell in line with the
majority of other analyses reporting a marked impact of
proximity-to-death on HCE growth, particularly those that
have also explored the role of morbidity by use of various
indicators. [4, 10, 17, 27] One of the most detailed ana-
lyses was performed by Wong and colleagues, who found
that proximity-to-death even holds within subgroups of
persons affected by 93 lethal and non-lethal diseases, but
with non-negligible age effects [27, 28] The wide inpatient
HCE variability between diseases suggested that HCE pro-
jections should also take the changing prevalence of spe-
cific diseases into account. [17, 29] Moreover, with its
population focus, the present work resembles the analyses
by Seshamani & Gray [11] who (and others [13]) also did
not observe continuous HCE growth among decedents.
Their estimated shares of decedent costs ranged from 19%
to 31% and were therefore similar to the ones observed in
this analysis (which, however, covered a longer and more
recent time period).
This work contributes to the ongoing debate on
age-related HCE drivers by analyzing data over a longer
time period than most other studies and by introducing
novel study design aspects, namely the simultaneous inves-
tigation of longitudinal HCE growth within contemporary
birth cohorts and across age classes over different years.
The availability of a large panel data set with complete
mortality information, combined with the chosen analytic
strategy allowed consistent control over a number of pos-
sible confounders (migration, sex or health status), which
may have affected other cross sectional based studies.
Novel findings of this study concerned the dynamics of
HCE volumes attributable to persons with imminent death,
which indeed tended to rise with increasing age. The
present analysis also yielded indications that, within the
same age class, the share of persons with imminent death
decreased over time. Of note, this finding was unlikely to
be caused by survivor bias because of the panel design of
this analysis and complete data on survival status. By con-
trast, the lack of morbidity indicators hampered insights
into further drivers for cost growth that were still subsumed
under age-associated effects in this analysis. Moreover, this
study did not specifically address the prevalent endogeneity
problem between health care expenditures and remaining
lifetime, and observed associations likely do not have a
causal interpretation. [7]
Conclusion
To conclude, this analysis pointed to a major, but not
exclusive role of proximity-to-death on HCE growth
among elderly. Falling in line with recent research, this
study confirmed that morbidity was a key factor pushing
HCE growth with rising age and that enhanced health
status indicators will be key to a better understanding of
age and “healthy aging” on overall HCE growth. These
results suggest that, given the residual age-associated
HCE growth observed in this study and the expected
demographic shift towards more elderly, further,
demography-related HCE growth is likely. Because of
the relevance of chronic morbidities in the observed
sample and the elderly population at large, potential
remedies to dampen the expected HCE increases may
include more efficient management of chronic illnesses
and potentially earlier and wider application of palliative
care. However, such measures should not solely focus on
elderly persons but include younger age classes, which
are also substantial contributors to overall HCE growth
and health care utilization expansion.
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